Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Cardiovascular adverse events induced by immune checkpoint inhibitors (ICIs) have gained significant interest over the past decade due to their impact on short- and long-term outcomes. They were initially thought to be rare, but the increasing use of ICIs in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in their incidence. Different guidelines have proposed screening measures for ICI-induced myocarditis by incorporating troponin measurements at baseline and during the first few weeks of treatment. However, no specific guidelines have been developed yet regarding the interpretation of an asymptomatic rise in troponins. This state-of-the art review aims to provide an overview of the clinical relevance of elevated troponins during checkpoint inhibition and recommendations on how to manage elevated troponin levels during ICI therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
ESMO open - 6(2021), 4 vom: 01. Aug., Seite 100216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Delombaerde, D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 29.10.2021 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2021.100216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328167215 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328167215 | ||
| 003 | DE-627 | ||
| 005 | 20240402234559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2021.100216 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM328167215 | ||
| 035 | |a (NLM)34271309 | ||
| 035 | |a (PII)S2059-7029(21)00177-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Delombaerde, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2021 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Cardiovascular adverse events induced by immune checkpoint inhibitors (ICIs) have gained significant interest over the past decade due to their impact on short- and long-term outcomes. They were initially thought to be rare, but the increasing use of ICIs in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in their incidence. Different guidelines have proposed screening measures for ICI-induced myocarditis by incorporating troponin measurements at baseline and during the first few weeks of treatment. However, no specific guidelines have been developed yet regarding the interpretation of an asymptomatic rise in troponins. This state-of-the art review aims to provide an overview of the clinical relevance of elevated troponins during checkpoint inhibition and recommendations on how to manage elevated troponin levels during ICI therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cardiac troponin | |
| 650 | 4 | |a cardiotoxicity | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a myocarditis | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Troponin |2 NLM | |
| 700 | 1 | |a Vervloet, D |e verfasserin |4 aut | |
| 700 | 1 | |a Franssen, C |e verfasserin |4 aut | |
| 700 | 1 | |a Croes, L |e verfasserin |4 aut | |
| 700 | 1 | |a Gremonprez, F |e verfasserin |4 aut | |
| 700 | 1 | |a Prenen, H |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, M |e verfasserin |4 aut | |
| 700 | 1 | |a Vulsteke, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 6(2021), 4 vom: 01. Aug., Seite 100216 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:4 |g day:01 |g month:08 |g pages:100216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2021.100216 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 4 |b 01 |c 08 |h 100216 | ||